Why Transcode Therapeutics (RNAZ) Stock Is Down 60%
Why Transcode Therapeutics (RNAZ) Stock Is Down 60%
Transcode Therapeutics Inc (NASDAQ:RNAZ) shares are trading lower by 62% to $0.30 during Tuesday's session after the company announced pricing of its public offering.
Transcode Therapeutics公司 (NASDAQ:RNAZ) 公開發行後股票價格下跌了62%，目前爲每股0.30美元，此次降價是該公司公開發行股票價格確定後宣佈的。
The public offering of 10 million shares of its common stock will be at $0.30 per share, aiming to raise $3 million before deducting expenses. The offering is set to close on July 24, pending usual conditions.
該公司公開發行了1000萬股普通股，每股的價格爲0.30美元，旨在籌集300萬美元（扣除費用後）。公開發行將於7月24日結束，前提是滿足一般條件。
The funds will be used for product development, including clinical trials for TTX-MC138, their lead therapeutic candidate, and related studies as well as for general corporate purposes.
所有基金類型將用於產品開發，包括首席治療候選人TTX-MC138的臨床試驗和相關研究，以及一般公司用途。
Read Also: Veteran Wall Street Investor Downplays Recession Odds: 'Current Bull Market Has More Support From Earnings'
同樣閱讀：資深華爾街投資者淡化了衰退的可能性：“當前的牛市從收益方面得到了更多的支持”
Should I Sell My RNAZ Stock?
我應該賣出RNAZ股票嗎？
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
是否賣出或持有某隻股票在很大程度上取決於投資者的策略和風險承受能力。波段交易者可以賣出表現良好的股票以鎖定資本收益，而長期投資者可能會在預期進一步股價增長的情況下忍受波動。
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
同樣，願意將損失最小化的交易者可能會出售下跌一定百分比的股票，而長期投資者則可能會將其視爲以折扣價買入更多股票的機會。
For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.
欲獲取分析工具、圖表數據和獨家股票新聞，請登錄Benzinga PRO。現在免費試用。
RNAZ has a 52-week high of $128.00 and a 52-week low of $0.30.
RNAZ的52周最高價爲128.00美元，52周最低價爲0.30美元。
譯文內容由第三人軟體翻譯。